JCNRJournal of Clinical and Nursing Research2208-36852208-3693Bio-Byword Scientific Publishing Pty. Ltd.10.26689/jcnr.v10i4.14468ArticleResearch Progress on the Mechanisms and Management Strategies of Pneumonia in Patients with Schizophreniahttps://artdesignp.com/journal/JCNR/10/4/10.26689/jcnr.v10i4.14468LuoXiaohong20261042026-04-30Patients with schizophrenia are at high risk of developing pneumonia, with significantly higher incidenceand mortality rates than the general population, a public health issue that warrants urgent attention. This articlesystematically reviews the epidemiological characteristics of pneumonia susceptibility in schizophrenia patients, deeplyexplores the multifaceted risk factors, including disease-specific features, antipsychotic medication effects, behavioraland lifestyle factors, and immune dysfunction. Based on this, the article further analyzes the core pathophysiologicalmechanisms underlying this susceptibility and comprehensively summarizes strategies for pneumonia prevention, earlyidentification, and treatment. By integrating the latest research evidence, this review aims to provide a theoretical basisfor developing targeted comprehensive management strategies in clinical practice, thereby improving the physical healthstatus and long-term prognosis of patients with schizophrenia.

Suetani S, Honarparvar F, Siskind D, et al., 2021, Increased Rates of Respiratory Disease in Schizophrenia: A Systematic Review and Meta-Analysis Including 619,214 Individuals with Schizophrenia and 52,159,551 Controls. Schizophrenia Research, 237: 131–140.

Luykx J, Correll C, Manu P, et al., 2024, Pneumonia Risk, Antipsychotic Dosing, and Anticholinergic Burden in Schizophrenia. JAMA Psychiatry, 81(10): 967–975.

Yang M, Li Q, Wang C, et al., 2021, Influencing Factors of Hospital-Acquired Pneumonia Infection in Middle-Aged and Elderly Patients with Schizophrenia. Frontiers in Psychiatry, 12: 746791.

Yang Y, Kong D, Li Q, et al., 2022, Non-antipsychotic Medicines and Modified Electroconvulsive Therapy Are Risk Factors for Hospital-Acquired Pneumonia in Schizophrenia Patients. Frontiers in Psychiatry, 13: 1071079.

Arai Y, Sasayama D, Kuraishi A, et al., 2023, Sodium Valproate Use in Japanese Patients with Schizophrenia and Coronavirus Disease Is Associated with an Increased Risk of Pneumonia. Journal of Clinical Medicine, 12(18): 5953.

Chen Y, Ren C, Liao Y, 2024, Analysis of Risk Factors for Hospital-Acquired Pneumonia in Schizophrenia. Frontiers in Psychiatry, 15: 1414332.

Yang Q, Huang S, Chen M, et al., 2022, Association of Ishii Test Scores with Pneumonia in Stable Schizophrenic Subjects. Frontiers in Psychiatry, 13: 1034905.

Cai D, Wang Y, Chen X, 2024, Relationship Between Nutrition Indicators and Pneumonia Risk Among Stable Schizophrenia Patients: A Retrospective Study. Psychogeriatrics, 24(4): 861–867.

Huang S, Chen M, Zhu T, et al., 2024, SARC-F, SARC-CalF, and SARC-F+EBM as Practical Predictive Tools for the Risk of Pneumonia in Patients with Stable Schizophrenia: A Prospective Study. Heliyon, 10(15): e34844.

Huang S, Zhu T, Chen M, et al., 2022, Association Between the Severity of Sarcopenia and Pneumonia in Patients with Stable Schizophrenia: A Prospective Study. Journal of Nutrition Health and Aging, 26(8): 799–805.

Zhao V, Gong Y, Thomas N, et al., 2024, Clozapine and Pneumonia: Synthesizing the Link by Reviewing Existing Reports—A Systematic Review and Meta-Analysis. Medicina, 60(12): 2016.

Maes M, Vojdani A, Sirivichayakul S, et al., 2021, Inflammatory and Oxidative Pathways Are New Drug Targets in Multiple Episode Schizophrenia and Leaky Gut, Klebsiella pneumoniae, and C1q Immune Complexes Are Additional Drug Targets in First Episode Schizophrenia. Molecular Neurobiology, 58(7): 3319–3334.

Jeon H, Kwon J, Park S, et al., 2021, Association of Mental Disorders with SARS-CoV-2 Infection and Severe Health Outcomes: Nationwide Cohort Study. British Journal of Psychiatry, 218(6): 344–351.

Nemani K, Li C, Olfson M, et al., 2021, Association of Psychiatric Disorders with Mortality Among Patients With COVID-19. JAMA Psychiatry, 78(4): 380–386.

Moga S, Teodorescu A, Ifteni P, et al., 2021, Inflammatory Response in SARS-CoV-2 Infection of Patients with Schizophrenia and Long-Term Antipsychotic Treatment. Neuropsychiatric Disease and Treatment, 17: 3053–3060.

Huang H, Wu B, Yu C, et al., 2025, LEPR Gene Polymorphisms and Pneumonia Risk in Taiwanese Schizophrenia Patients Under Clozapine Treatment. Schizophrenia Research, 278: 1–8.

Hashimoto K, 2025, Host Microbiota in Clozapine-Induced Ileus and Pneumonia Among People with Schizophrenia. British Journal of Psychiatry, 227(2): 574–575.

Chang C, Chen P, Pan C, et al., 2020, Antipsychotic Medications and the Progression of Upper Respiratory Infection to Pneumonia in Patients with Schizophrenia. Schizophrenia Research, 222: 327–334.

May M, Slitzky M, Rostama B, et al., 2020, Antipsychotic-Induced Immune Dysfunction: A Consideration for COVID-19 Risk. Brain Behavior and Immunity Health, 6: 100097.

Yang M, Yang Y, Liu L, et al., 2023, Sex Differences in Factors Influencing Hospital-Acquired Pneumonia in Schizophrenia Patients Receiving Modified Electroconvulsive Therapy. Frontiers in Psychiatry, 14: 1127262.

Djurdjevic N, Taweesedt P, Paulson M, et al., 2020, Septic Shock and Purpura Fulminans Due to Streptococcus pneumoniae Bacteremia in an Unvaccinated Immunocompetent Adult: Case Report and Review. American Journal of Case Reports, 21: e923266.

Ren S, Huang S, Chen M, et al., 2022, Association Between Mid-Upper Arm Circumference and Calf Circumference Screening Indicators of Sarcopenia with the Risk of Pneumonia in Stable Patients Diagnosed with Schizophrenia. Frontiers in Psychiatry, 13: 931933.

Yokoyama A, Jo T, Sakamoto Y, et al., 2023, Effectiveness and Safety of the Co-administration of Yokukan-San with Antipsychotics in Hospitalized Older Patients with Pneumonia. Geriatrics and Gerontology International, 23(11): 849–854.

Cepaityte D, Siafis S, Egberts T, et al., 2021, Exploring a Safety Signal of Antipsychotic-Associated Pneumonia: A Pharmacovigilance-Pharmacodynamic Study. Schizophrenia Bulletin, 47(3): 672–681.